RU2015120645A - Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) - Google Patents
Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) Download PDFInfo
- Publication number
- RU2015120645A RU2015120645A RU2015120645A RU2015120645A RU2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A RU 2015120645 A RU2015120645 A RU 2015120645A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- oligonucleotide
- fgfr3
- oligonucleotide according
- expression
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 210000002950 fibroblast Anatomy 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 19
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 12
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 12
- 108020004999 messenger RNA Proteins 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 208000014884 cartilage development disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261729922P | 2012-11-26 | 2012-11-26 | |
| US61/729,922 | 2012-11-26 | ||
| PCT/EP2013/074552 WO2014080004A1 (en) | 2012-11-26 | 2013-11-25 | Compositions and methods for modulation of fgfr3 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015120645A true RU2015120645A (ru) | 2017-01-10 |
Family
ID=49639882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120645A RU2015120645A (ru) | 2012-11-26 | 2013-11-25 | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9725723B2 (enExample) |
| EP (1) | EP2922955B1 (enExample) |
| JP (1) | JP6463687B2 (enExample) |
| KR (1) | KR20150088305A (enExample) |
| CN (1) | CN104903448B (enExample) |
| BR (1) | BR112015012051A2 (enExample) |
| CA (1) | CA2889993A1 (enExample) |
| DK (1) | DK2922955T3 (enExample) |
| MX (1) | MX2015006289A (enExample) |
| RU (1) | RU2015120645A (enExample) |
| WO (1) | WO2014080004A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CA2817960C (en) | 2010-11-17 | 2020-06-09 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| WO2014080004A1 (en) | 2012-11-26 | 2014-05-30 | Santaris Pharma A/S | Compositions and methods for modulation of fgfr3 expression |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| TWI857207B (zh) * | 2020-01-31 | 2024-10-01 | 國立大學法人京都大學 | 軟骨發育異常症之治療 |
| WO2022211095A1 (ja) * | 2021-03-31 | 2022-10-06 | ルクサナバイオテク株式会社 | Ｆｇｆｒ３のアンチセンスオリゴヌクレオチド |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
| US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| JPH08504559A (ja) | 1992-12-14 | 1996-05-14 | ハネウエル・インコーポレーテッド | 個別に制御される冗長巻線を有するモータシステム |
| US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| EP1964837A4 (en) * | 2005-11-22 | 2010-12-22 | Eisai R&D Man Co Ltd | Antitumor agent against multiple myeloma |
| WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| MX2009002859A (es) | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos. |
| WO2008034123A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| CN101554074B (zh) | 2006-10-30 | 2012-08-22 | 诺基亚公司 | 为用户设备提供运营商控制的移动性的方法、设备和系统 |
| DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
| MA33208B1 (fr) * | 2009-03-25 | 2012-04-02 | Genentech Inc | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci |
| WO2011139843A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
| US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
| WO2014080004A1 (en) | 2012-11-26 | 2014-05-30 | Santaris Pharma A/S | Compositions and methods for modulation of fgfr3 expression |
| US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2013
- 2013-11-25 WO PCT/EP2013/074552 patent/WO2014080004A1/en not_active Ceased
- 2013-11-25 RU RU2015120645A patent/RU2015120645A/ru not_active Application Discontinuation
- 2013-11-25 JP JP2015543449A patent/JP6463687B2/ja not_active Expired - Fee Related
- 2013-11-25 DK DK13795243.8T patent/DK2922955T3/da active
- 2013-11-25 CN CN201380061132.9A patent/CN104903448B/zh not_active Expired - Fee Related
- 2013-11-25 KR KR1020157016841A patent/KR20150088305A/ko not_active Withdrawn
- 2013-11-25 US US14/647,430 patent/US9725723B2/en not_active Expired - Fee Related
- 2013-11-25 BR BR112015012051A patent/BR112015012051A2/pt active Search and Examination
- 2013-11-25 CA CA2889993A patent/CA2889993A1/en not_active Abandoned
- 2013-11-25 EP EP13795243.8A patent/EP2922955B1/en not_active Not-in-force
- 2013-11-25 MX MX2015006289A patent/MX2015006289A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1208702A1 (en) | 2016-03-11 |
| CA2889993A1 (en) | 2014-05-30 |
| MX2015006289A (es) | 2015-12-03 |
| KR20150088305A (ko) | 2015-07-31 |
| US9725723B2 (en) | 2017-08-08 |
| CN104903448A (zh) | 2015-09-09 |
| BR112015012051A2 (pt) | 2017-12-12 |
| US20150307886A1 (en) | 2015-10-29 |
| EP2922955A1 (en) | 2015-09-30 |
| EP2922955B1 (en) | 2019-03-06 |
| WO2014080004A1 (en) | 2014-05-30 |
| DK2922955T3 (da) | 2019-05-13 |
| JP6463687B2 (ja) | 2019-02-06 |
| CN104903448B (zh) | 2017-07-11 |
| JP2016501520A (ja) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015120645A (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 3 типа (fgfr3) | |
| TWI606059B (zh) | 反意義核酸 | |
| DK3118311T3 (en) | Antisense nucleic acid | |
| CN106661577B (zh) | 反义核酸 | |
| TWI725990B (zh) | 反義核酸 | |
| AU2017224226A1 (en) | Compositions and methods of using piRNAs in cancer diagnostics and therapeutics | |
| RU2018119315A (ru) | Олигонуклеотиды для индуцирования отцовской экспрессии ube3a | |
| CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| JP2013510561A5 (enExample) | ||
| JP2010524486A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2023158214A (ja) | Ｈｉｆ２αの遺伝子発現を阻害する組成物及び方法 | |
| JP2008532477A5 (enExample) | ||
| JP2011524745A5 (enExample) | ||
| TW200927176A (en) | RNA antagonist compounds for the modulation of PIK3CA expression | |
| TW201036619A (en) | Methods of treating cancers with HER3 antisense oligonucleotides | |
| TW201016222A (en) | RNA antagonists targeting GLI2 | |
| CN113728102A (zh) | 使用剪接调节化合物进行新抗原工程化 | |
| KR20160098097A (ko) | 마이크로알앤에이 검출용 키트 및 방법 | |
| JPWO2017047741A1 (ja) | 筋萎縮症治療用アンチセンス核酸 | |
| EP3898975A2 (en) | Antisense oligonucleotides targeting card9 | |
| EP2175023A1 (en) | Anti-tumor activity of small double-stranded oligodeoxynucleotides targeting telomerase RNA | |
| RU2024128257A (ru) | Общие неоантигены | |
| TW201102073A (en) | RNA antagonists targeting GLI2 for the treatment of leukemia | |
| WO2020007772A1 (en) | Antisense oligonucleotides targeting gbp-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20181126 |